Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual house dust mite immunotherapy in adult allergic rhinitis (Phase II/III)
2007-001454-77Phase 2Completed
- Sponsor
- Stallergenes Greer
- Start
- Jun 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of House dust mite allergen extract in allergic rhinitis (AR) and house dust mite allergic rhinitis (3 arms), sponsored by Stallergenes Greer. Primary endpoint: Average Adjusted Symptom Score (AASS) during increased symptom period. Started Jun 2007; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)house dust mite allergic rhinitis
Beyond the preview
Go deeper on 2007-001454-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001454-77.